⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Official Title: A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Study ID: NCT01922102

Study Description

Brief Summary: This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Detailed Description: This was a phase III, multi-center, randomized, double-masked, active-controlled study comparing 0.5 mg ranibizumab vs. vPDT therapy. The study included 15 scheduled visits over 12 months, and there were to be two additional visits (2a, 3a) for subset of patients in whom PK analysis were performed. There were 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients entered the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria were met and were randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or Group III vPDT (randomization ratio of 2:2:1) and received first treatment of either a ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the clinical center within 7 days to undergo safety assessments as well as assessments of the effect of treatment by the evaluating investigator. The following visits were performed at one month intervals starting at Visit 4 and continuing through Visit 14. At all monthly visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III) the decision for treatment were made by the evaluating investigator based on the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all following monthly visits for all three groups one of the three options can recommended by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The treating investigator were then perform treatment based on randomization and masking requirements. At each monthly visit, patients had a safety evaluation by the evaluating investigator prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations and evaluation of adverse events and vital signs. Routine hematology, chemistry, and urinalysis profiles were obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12 several procedures and assessments were performed which are required at study completion visit.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Novartis Investigative Site, Beijing, Beijing, China

Novartis Investigative Site, Beijing, Beijing, China

Novartis Investigative Site, Chongqing, Chongqing, China

Novartis Investigative Site, Shantou, Guangdong, China

Novartis Investigative Site, Harbin, Heilongjiang, China

Novartis Investigative Site, Wuhan, Hubei, China

Novartis Investigative Site, Wuhan, Hubei, China

Novartis Investigative Site, Changsha, Hunan, China

Novartis Investigative Site, Changsha, Hunan, China

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Nanjing, Jiangsu, China

Novartis Investigative Site, Wu XI, Jiangsu, China

Novartis Investigative Site, Nanchang, Jiangxi, China

Novartis Investigative Site, Qingdao, Shandong, China

Novartis Investigative Site, Xi'an, Shanxi, China

Novartis Investigative Site, Chengdu, Sichuan, China

Novartis Investigative Site, Tianjin, Tianjin, China

Novartis Investigative Site, Tianjin, Tianjin, China

Novartis Investigative Site, Hangzhou, Zhejiang, China

Novartis Investigative Site, Wenzhou, Zhejiang, China

Novartis Investigative Site, Beijing, , China

Novartis Investigative Site, Beijing, , China

Novartis Investigative Site, Beijing, , China

Novartis Investigative Site, Chongqing, , China

Novartis Investigative Site, Shanghai, , China

Novartis Investigative Site, Shanghai, , China

Novartis Investigative Site, Shanghai, , China

Novartis Investigative Site, Hongkong, , Hong Kong

Novartis Investigative Site, Chandigarh, Haryana, India

Novartis Investigative Site, Bangalore, Karnataka, India

Novartis Investigative Site, Vanchiyoor, Kerala, India

Novartis Investigative Site, Bhubaneswar, Orissa, India

Novartis Investigative Site, Chennai, Tamil Nadu, India

Novartis Investigative Site, Chennai, Tamil Nadu, India

Novartis Investigative Site, Coimbatore, Tamil Nadu, India

Novartis Investigative Site, Hyderabad, Telangana, India

Novartis Investigative Site, Angamaly, , India

Novartis Investigative Site, New Delhi, , India

Novartis Investigative Site, Pusan, , Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Manila, Metro Manila, Philippines

Novartis Investigative Site, Manila, Metro Manila, Philippines

Novartis Investigative Site, Khon Kaen, THA, Thailand

Novartis Investigative Site, Bangkok, , Thailand

Novartis Investigative Site, Chiang Mai, , Thailand

Novartis Investigative Site, Nakornphathom, , Thailand

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: